5-methyl-4-[(2-methyl-5-{[(3-morpholin-4-ylphenyl)carbonyl]amino}phenyl)amino]-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide | 623153-31-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-methyl-4-[(2-methyl-5-{[(3-morpholin-4-ylphenyl)carbonyl]amino}phenyl)amino]-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
• 英文别名: 5-methyl-4-[2-methyl-5-[(3-morpholin-4-ylbenzoyl)amino]anilino]-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
• CAS: 623153-31-1
• 化学式: C₃₄H₃₅N₇O₃
• 分子量: 589.697
• InChiKey: KYFKCMGDXJZZIZ-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  44
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-Methyl-4-[2-methyl-5-[(3-morpholin-4-ylbenzoyl)amino]anilino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 、 (S)-(-)- α-甲基苄胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-methyl-4-[(2-methyl-5-{[(3-morpholin-4-ylphenyl)carbonyl]amino}phenyl)amino]-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  参考文献：
  名称：

  新型吡咯并[2,1-f] [1,2,4]三嗪作为有效的p38αMAP激酶抑制剂的合成和SAR。

  摘要：

  基于吡咯并[2,1-f] [1,2,4]三嗪环系统的一系列新化合物已被鉴定为有效的p38αMAP激酶抑制剂。报道了从这类抑制剂中选择的类似物的合成，结构-活性关系（SAR）和体内活性。基于X射线共晶体的其他研究表明，该系列的有效抑制剂之一与p38α酶的DFG-out构象结合。

  DOI：

  10.1016/j.bmcl.2008.02.067

文献信息

• Medicament for the treatment of liver cancer
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP2543372A1

  公开（公告）日：2013-01-09

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。
• Medicament for treatment of liver cancer
  申请人：Zender Lars

  公开号：US10441577B2

  公开（公告）日：2019-10-15

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。
• Pyrrolo-triazine aniline compounds useful as kinase inhibitors
  申请人：Dyckman Alaric

  公开号：US20070043053A1

  公开（公告）日：2007-02-22

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.
• Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors
  申请人：Dyckman Alaric

  公开号：US20090105243A1

  公开（公告）日：2009-04-23

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.
• PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Dyckman Alaric

  公开号：US20100240646A1

  公开（公告）日：2010-09-23

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.